Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab

References

• Yao Y, Lin X, Li F, et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the Global Burden of Disease study 2019. Biomed Eng Online. 2022;21(1):4. doi: 10.1186/s12938-021-00973-6.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33. doi: 10.1016/j.annonc.2020.09.019.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER Cancer Stat Facts: chronic lymphocytic leukemia/small lymphocytic lymphoma. [cited 2023 Jun 25]. Available from: https://seer.cancer.gov/statfacts/html/cllsll.html
   Google Scholar
• Waweru C, Kaur S, Sharma S, et al. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Curr Med Res Opin. 2020;36(9):1481–1495. doi: 10.1080/03007995.2020.1784120.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Signs and symptoms of chronic lymphocytic leukemia. [cited 2023 Jun 25]. Available from: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/detection-diagnosis-staging/signs-symptoms.html
   Google Scholar
• Holtzer-Goor KM, Schaafsma MR, Joosten P, et al. Quality of life of patients with chronic lymphocytic leukaemia in The Netherlands: results of a longitudinal multicentre study. Qual Life Res. 2015;24(12):2895–2906. doi: 10.1007/s11136-015-1039-y.
   PubMed Web of Science ®Google Scholar
• Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020(1):336–345. doi: 10.1182/hematology.2020000118.
   PubMedGoogle Scholar
• Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139(2):255–264. doi: 10.1111/j.1365-2141.2007.06791.x.
   PubMed Web of Science ®Google Scholar
• Scheffold A, Stilgenbauer S. Revolution of chronic lymphocytic leukemia therapy: the chemo-free treatment paradigm. Curr Oncol Rep. 2020;22(2):16. doi: 10.1007/s11912-020-0881-4.
   PubMed Web of Science ®Google Scholar
• Smolej L, Vodárek P, Écsiová D, et al. Chemoimmunotherapy in the first-line treatment of chronic lymphocytic leukaemia: dead yet, or alive and kicking? Cancers (Basel). 2021;13(13):3134. doi: 10.3390/cancers13133134.
   PubMed Web of Science ®Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798. doi: 10.1038/s41375-019-0602-x.
   PubMed Web of Science ®Google Scholar
• Cramer P, Fraser G, Santucci-Silva R, et al. Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Leuk Lymphoma. 2018;59(9):2075–2084. doi: 10.1080/10428194.2017.1416364.
   PubMed Web of Science ®Google Scholar
• GlobeNewswire. BeiGene announces the approval of BRUKINSATM (zanubrutinib) in China for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma and relapsed/refractory mantle cell lymphoma; 2020 [cited 2023 Jun 25]. Available from: https://www.globenewswire.com/news-release/2020/06/03/2042805/0/en/BeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-Chinafor-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html
   Google Scholar
• Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62(17):7923–7940. doi: 10.1021/acs.jmedchem.9b00687.
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–2050. doi: 10.1182/blood.2020006844.
   PubMed Web of Science ®Google Scholar
• Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–1043. doi: 10.1016/s1470-2045(22)00293-5.
   PubMed Web of Science ®Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. Int Dig Health Legis. 1997;48(2):231–234.
   PubMedGoogle Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736. doi: 10.1007/s11136-011-9903-x.
   PubMed Web of Science ®Google Scholar
• Kemmler G, Holzner B, Kopp M, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17(9):2932–2940. doi: 10.1200/jco.1999.17.9.2932.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2022.
   Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–144. doi: 10.1200/jco.1998.16.1.139.
   PubMed Web of Science ®Google Scholar
• Shields A, Coon C, Hao Y, et al. Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):951–959. doi: 10.1586/14737167.2015.1115348.
   PubMed Web of Science ®Google Scholar
• Sloan JA, Dueck AC, Erickson PA, et al. Analysis and interpretation of results based on patient-reported outcomes. Value Health. 2007;10(Suppl 2):S106–S115. doi: 10.1111/j.1524-4733.2007.00273.x.
   PubMedGoogle Scholar
• Müller D, Fischer K, Kaiser P, et al. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(5):1130–1139. doi: 10.3109/10428194.2015.1070151.
   PubMed Web of Science ®Google Scholar
• van de Poll-Franse L, Oerlemans S, Bredart A, et al. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Qual Life Res. 2018;27(2):333–345. doi: 10.1007/s11136-017-1718-y.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Janssens A, Babu KG, et al. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL. Acta Oncol. 2016;55(9-10):1115–1120. doi: 10.1080/0284186x.2016.1205217.
   PubMed Web of Science ®Google Scholar
• Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386(26):2482–2494. doi: 10.1056/NEJMoa2201817.
   PubMed Web of Science ®Google Scholar